MA38645A1 - Nouveaux inhibiteurs de cyp17/antiandrogènes - Google Patents

Nouveaux inhibiteurs de cyp17/antiandrogènes

Info

Publication number
MA38645A1
MA38645A1 MA38645A MA38645A MA38645A1 MA 38645 A1 MA38645 A1 MA 38645A1 MA 38645 A MA38645 A MA 38645A MA 38645 A MA38645 A MA 38645A MA 38645 A1 MA38645 A1 MA 38645A1
Authority
MA
Morocco
Prior art keywords
cyp17
antiandrogens
new inhibitors
inhibitors
new
Prior art date
Application number
MA38645A
Other languages
English (en)
Other versions
MA38645B1 (fr
Inventor
Eija Tiainen
Gerd Wohlfahrt
Petteri Rummakko
Arja Karjalainen
Mikko Passiniemi
Pekka Pietikäinen
Anssi Haikarainen
Emilia Väisänen
Original Assignee
Orion Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Corp filed Critical Orion Corp
Publication of MA38645A1 publication Critical patent/MA38645A1/fr
Publication of MA38645B1 publication Critical patent/MA38645B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/58—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

L'invention concerne des composés de formule (i), dans laquelle r
MA38645A 2013-06-11 2014-06-10 Nouveaux inhibiteurs de cyp17/antiandrogènes MA38645B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361833846P 2013-06-11 2013-06-11
PCT/FI2014/000009 WO2014202827A1 (fr) 2013-06-11 2014-06-10 Nouveaux inhibiteurs de cyp17/antiandrogènes

Publications (2)

Publication Number Publication Date
MA38645A1 true MA38645A1 (fr) 2018-05-31
MA38645B1 MA38645B1 (fr) 2018-11-30

Family

ID=51062835

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38645A MA38645B1 (fr) 2013-06-11 2014-06-10 Nouveaux inhibiteurs de cyp17/antiandrogènes

Country Status (21)

Country Link
US (1) US9890139B2 (fr)
EP (1) EP3008042A1 (fr)
JP (1) JP6356790B2 (fr)
KR (1) KR20160019928A (fr)
CN (1) CN105339355B (fr)
AR (1) AR101051A1 (fr)
AU (1) AU2014283150B2 (fr)
CA (1) CA2912166A1 (fr)
CL (1) CL2015003595A1 (fr)
EA (1) EA029280B1 (fr)
HK (1) HK1220690A1 (fr)
MA (1) MA38645B1 (fr)
MX (1) MX2015016943A (fr)
PE (1) PE20160050A1 (fr)
PH (1) PH12015502723A1 (fr)
SA (1) SA515370266B1 (fr)
SG (1) SG11201509449XA (fr)
TW (1) TW201534586A (fr)
UA (1) UA116808C2 (fr)
WO (1) WO2014202827A1 (fr)
ZA (1) ZA201508398B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170327469A1 (en) 2015-01-20 2017-11-16 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
KR20230119040A (ko) 2015-01-20 2023-08-14 아비나스 오퍼레이션스, 인코포레이티드 안드로겐 수용체의 표적화된 분해를 위한 화합물 및방법
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
AR110412A1 (es) * 2016-12-22 2019-03-27 Orion Corp Inhibidores de la cyp11a1
WO2018165520A1 (fr) 2017-03-10 2018-09-13 Vps-3, Inc. Composés inhibiteurs de métalloenzymes
TWI692679B (zh) * 2017-12-22 2020-05-01 美商慧盛材料美國責任有限公司 光阻剝除劑
CN108586443B (zh) * 2018-01-31 2019-11-26 佳木斯大学附属第一医院 一种防治支气管肺癌的药物及其制备方法
CN114235972B (zh) * 2021-10-28 2023-08-22 乳源东阳光药业有限公司 一种测定利格列汀杂质rbp-1含量的方法
WO2023091726A1 (fr) * 2021-11-18 2023-05-25 Syros Pharmaceuticals, Inc. Inhibiteurs de la kinase 12 dépendante de la cycline (cdk12)
CN114369030A (zh) * 2022-01-14 2022-04-19 浙江大学衢州研究院 一种2,2,4,4-四甲基-1,3-环丁二胺的制备方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4546194A (en) 1984-05-29 1985-10-08 G. D. Searle & Co. Substituted chromanon-2-yl alkanols and derivatives thereof
DE3879024T2 (de) 1987-07-31 1993-10-07 Takeda Chemical Industries Ltd Pyridinium-Derivate, ihre Herstellung und Verwendung.
PT1250340E (pt) 1999-12-22 2005-04-29 Lilly Co Eli Metodos e compostos para inibicao de mrp1
JP4272338B2 (ja) 2000-09-22 2009-06-03 バイエル アクチェンゲゼルシャフト ピリジン誘導体
AU2003220935A1 (en) * 2002-04-03 2003-10-13 Sumitomo Pharmaceuticals Company, Limited. Benzamide derivatives
EP1654221A2 (fr) 2003-06-10 2006-05-10 Smithkline Beecham Corporation Modulateurs de recepteurs androgene, glucocorticoide, mineralcorticoide, progesterone bases sur des derives d' aniline
WO2005075426A1 (fr) 2004-02-03 2005-08-18 Glenmark Pharmaceuticals Ltd. Nouveaux inhibiteurs de dipeptidyle peptidase iv, leur procedes de preparation et compositions en comportant
US20080045504A1 (en) 2004-05-11 2008-02-21 Pfizer Products Inc. Benzonitrile Derivatives to Treat Musculoskeletal Frailty
US7834063B2 (en) 2004-10-13 2010-11-16 Glaxosmithkline Llc Benzonitryl and nitrobenzyl derivatives that modulate androgen receptors
DK1836211T3 (da) 2004-12-21 2010-05-17 Pfizer Prod Inc Makrolider
EP1879575A2 (fr) 2005-05-09 2008-01-23 Achillion Pharmaceuticals, Inc. Composes thiazole et procedes d'utilisation
JP2008546643A (ja) 2005-06-06 2008-12-25 スミスクライン ビーチャム コーポレーション ４−置換アリールアミン誘導体および医薬組成物におけるその使用
EP1954133A4 (fr) 2005-11-30 2010-11-24 Glaxosmithkline Llc Pyrrolidine-anilines
WO2007092727A1 (fr) 2006-02-10 2007-08-16 Janssen Pharmaceutica N.V. Nouveaux dérivés d'imidazolopyrazole utiles comme modulateurs sélectifs du récepteur de l'androgène
WO2007099385A1 (fr) 2006-03-01 2007-09-07 Glenmark Pharmaceuticals S.A. Composés inhibiteurs de dipeptidylpeptidase iv et compositions correspondantes
EA200970189A1 (ru) * 2006-08-09 2009-08-28 Смитклайн Бичам Корпорейшн Пирролидинонанилины как модуляторы прогестероновых рецепторов
WO2008077089A1 (fr) 2006-12-19 2008-06-26 Smithkline Beecham Corporation Pyrrolidinanilines
US8013169B2 (en) 2007-01-12 2011-09-06 Allergan, Inc Naphthylmethylimidizoles as therapeutic agents
WO2009124882A1 (fr) 2008-04-09 2009-10-15 H. Lundbeck A/S Nouvelles pipéridinyl-1,3-dihydrobenzoimidazol-2-ones comme agonistes de m1
WO2009131196A1 (fr) * 2008-04-24 2009-10-29 武田薬品工業株式会社 Dérivé de pyrrolidine substituée et ses utilisations
EP2202232A1 (fr) 2008-12-26 2010-06-30 Laboratorios Almirall, S.A. Dérivés du 1,2,4-oxadiazole et leur application thérapeutique
UA105794C2 (uk) * 2009-06-26 2014-06-25 Новартіс Аг 1,3-ДИЗАМІЩЕНІ ПОХІДНІ ІМІДАЗОЛІДИН-2-ОНУ ЯК ІНГІБІТОРИ Cyp17
CN102834380B (zh) 2010-03-10 2015-04-01 阿斯利康公司 蛋白激酶的抑制剂
US8916553B2 (en) 2010-07-26 2014-12-23 Bristol-Myers Squibb Company Sulfonamide compounds useful as CYP17 inhibitors
CA2808543C (fr) * 2010-08-20 2016-01-26 Hutchison Medipharma Limited Composes de pyrrolopyrimidine et leurs utilisations
CN102372717B (zh) * 2010-08-20 2014-06-18 和记黄埔医药（上海）有限公司 吡咯并嘧啶类化合物及其用途
EP2685981B1 (fr) 2011-03-17 2016-08-24 Bristol-Myers Squibb Company Inhibiteurs de jak3 de type pyrrolopyridazine et leur utilisation pour traiter les maladies inflammatoires et auto-immunes
EP2520566A1 (fr) 2011-05-06 2012-11-07 Orion Corporation Nouveaux composés pharmaceutiques
AR088082A1 (es) * 2011-10-13 2014-05-07 Lilly Co Eli Moduladores selectivos del receptor androgeno
EP2882733B1 (fr) * 2012-08-08 2017-04-26 Novartis Tiergesundheit AG Azines substitues comme pesticides

Also Published As

Publication number Publication date
AU2014283150B2 (en) 2018-05-10
CN105339355A (zh) 2016-02-17
EP3008042A1 (fr) 2016-04-20
AU2014283150A1 (en) 2015-12-03
CN105339355B (zh) 2018-02-27
US20160130254A1 (en) 2016-05-12
CL2015003595A1 (es) 2016-07-08
UA116808C2 (uk) 2018-05-10
TW201534586A (zh) 2015-09-16
JP6356790B2 (ja) 2018-07-11
SG11201509449XA (en) 2015-12-30
PH12015502723B1 (en) 2016-03-14
SA515370266B1 (ar) 2018-04-15
HK1220690A1 (zh) 2017-05-12
MX2015016943A (es) 2016-04-25
JP2016523851A (ja) 2016-08-12
PE20160050A1 (es) 2016-02-18
US9890139B2 (en) 2018-02-13
CA2912166A1 (fr) 2014-12-24
EA029280B1 (ru) 2018-03-30
KR20160019928A (ko) 2016-02-22
MA38645B1 (fr) 2018-11-30
AR101051A1 (es) 2016-11-23
WO2014202827A1 (fr) 2014-12-24
ZA201508398B (en) 2017-06-28
PH12015502723A1 (en) 2016-03-14
EA201592294A1 (ru) 2016-05-31

Similar Documents

Publication Publication Date Title
MA38645A1 (fr) Nouveaux inhibiteurs de cyp17/antiandrogènes
MA35926B1 (fr) Pyrrolidine-2-carboxamides substitués
MA35089B1 (fr) Inhibiteurs de la production de leucotrienes de type benzodioxane
CO6852084A2 (es) Nuevos compuestos sustituidos con halógeno
CR20130045A (es) Compuestos terapéuticos
CR20140468A (es) Inhibidores de diacilglicerol aciltransferasa 2
EA201690172A1 (ru) Полиморф ингибиторов syk
UA110338C2 (en) Chemical compounds
MA37959A2 (fr) Dérivés de 5-phénoxy-3h-pyrimidin-4-one et leur utilisation en tant qu'inhibiteurs de la transcriptase inverse du vih
MA35357B1 (fr) Composes de type anilines
CR20140510A (es) Nucleósidos de espirooxetano de uracilo
EA201690473A1 (ru) Комбинированный состав двух противовирусных соединений
CR20140042A (es) Indazoles
CR20130369A (es) Novedosos derivados heterocíclicos
TR201900038T4 (tr) GPR6'nın tetrahidropiridopirazin modülatörleri.
UY34825A (es) Síntesis de compuestos heterocíclicos
MA34389B1 (fr) Nouvelles aminopyrazoloquinazolines
UA111626C2 (uk) Похідні дигідрохінолін-2-ону
CR20150271A (es) Peptidos como agonistas de oxitocina
UA113062C2 (xx) Похідні 5-фтор-4-іміно-3-(заміщеного)-3,4-дигідропіримідин-2(1h)ону
MA35086B1 (fr) Compose de triazolopyridine
RS54730B1 (sr) Inhibitori beta sekretaze
MA35049B1 (fr) Triazolopyridines
EA201691141A1 (ru) Соединения против ccr6
MA37686A1 (fr) Composés phénoxyéthyl pipéridine